Celsion (NASDAQ: CLSN) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Celsion to similar companies based on the strength of its valuation, institutional ownership, dividends, profitability, risk, earnings and analyst recommendations.

Risk & Volatility

Celsion has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Celsion’s rivals have a beta of 0.63, indicating that their average share price is 37% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Celsion and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celsion 0 0 4 0 3.00
Celsion Competitors 864 3216 11668 232 2.71

Celsion currently has a consensus target price of $14.50, indicating a potential upside of 416.01%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.14%. Given Celsion’s stronger consensus rating and higher probable upside, analysts plainly believe Celsion is more favorable than its rivals.

Institutional & Insider Ownership

4.2% of Celsion shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.8% of Celsion shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Celsion and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Celsion $500,000.00 -$22.05 million -0.48
Celsion Competitors $284.28 million $33.78 million 80.42

Celsion’s rivals have higher revenue and earnings than Celsion. Celsion is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Celsion and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celsion -4,537.06% -381.17% -81.74%
Celsion Competitors -5,361.25% -213.57% -39.75%


Celsion rivals beat Celsion on 7 of the 12 factors compared.

Celsion Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.